^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Endometrial Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/20/2023
    Excerpt:
    Endometrial Carcinoma: SYSTEMIC THERAPY FOR ENDOMETRIAL CARCINOMA…Useful in Certain Circumstances…ER-positive tumors...Letrozole/abemaciclib…
    Secondary therapy:
    letrozole
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models

    Published date:
    05/15/2020
    Excerpt:
    Combination treatment with letrozole and abemaciclib was significantly more efficacious when compared with either drug alone, in both SKOV3 and Ishikawa. The CI values (0.5 and 0.7, respectively) demonstrated potent synergism in these ER+…
    Secondary therapy:
    letrozole
    DOI:
    10.1158/1538-7445.AM2020-4851